SCHEMBL1419657

SCHEMBL1419657

O=Cc1ccc(N2CCOCC2)cc1C(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 2/20 0.62
PIK3CD O00329 1/20 0.62
PIK3CA P42336 1/20 0.62
PIK3CB P42338 1/20 0.62
PIK3CG P48736 1/20 0.62
ALDH1A1 P00352 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
MITF O75030 1/20 0.44
HPGD P15428 1/20 0.44
NTSR1 P30989 1/20 0.44
ERN1 O75460 1/20 0.44
NOTUM Q6P988 1/20 0.43
AKR1C3 P42330 1/20 0.43
THRB P10828 1/20 0.42
LGMN Q99538 1/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20557106 0.86 ALDH1A1 (0.55) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3930853 0.80 PRKDC (0.68) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL20571928 0.79 NOTUM (0.47) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL15093771 0.79 PRKDC (0.58) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6224618 0.78 PIK3CD (0.69) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1894868 0.78 PRKDC (0.64) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6248711 0.77 PIK3CD (0.68) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30822010 0.77 MAPT (0.49) PRKDCPIK3CAALDH1A1MEN1KMT2A
SCHEMBL6237204 0.77 PRKDC (0.68) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL12059104 0.77 MAPT (0.49) PRKDCPIK3CAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 CN disclosed
US-12018004-B2 Carbamate compounds and methods of making and using same H. LUNDBECK A/S (DK) 2024-06-25 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
WO-2013103973-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-07-11 WO disclosed
CN-102112475-A Imidazopyridine and related analogs as sirtuin modulators SIRTRIS PHARMACEUTICALS INC 2011-06-29 CN disclosed
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. 2011-03-31 US disclosed
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. 2011-03-31 US disclosed
EP-2297144-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-03-23 EP disclosed
WO-2009146358-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
WO-2009146358-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
EP-1572693-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS Pharmacia Corporation (US) 2005-09-14 EP disclosed
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds PHARMACIA CORPORATION 2004-10-21 US disclosed
WO-2004058762-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL PRKDC 2654/4885PIK3CD 697/4885PIK3CA 449/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL PRKDC 2429/4885PIK3CD 590/4885PIK3CA 405/4885
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PRKDC 3152/4885PIK3CD 1053/4885PIK3CA 1961/4885
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds MAPKAPK2, MAP3K2, MKNK2 PRKDC 193/4885PIK3CD 285/4885PIK3CA 303/4885
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 PRKDC 1939/4885PIK3CD 900/4885PIK3CA 1936/4885
US-12018004-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 PRKDC 1939/4885PIK3CD 900/4885PIK3CA 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.